Drug Database
AL

albumin (Zenalb)

✓ Approved

Kedrion · 细胞治疗 · 细胞治疗

什么是 albumin?

albumin 是一种细胞治疗,由Kedrion研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Zenalb
公司Kedrion
药物类别细胞治疗
给药途径Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

albumin 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersThrombosis✓ Approved

相关研究文献

PubMedBMC cancer2026-11-19

Pulmonary embolism in lung cancer: a retrospective exploratory study.

Shang Junyi J, Wu Zhuhua Z, Jiang Miao M, Yuan Lin L et al.

Lung cancer is associated with a high risk of venous thromboembolism, and pulmonary embolism (PE) is a critical complication. The synchronous diagnosis of PE at the initial presentation of lung cancer presents diagnostic challenges and affects management. The predictive factors for this dual diagnosis remain poorly defined. A retrospective comparative study was conducted on 251 newly diagnosed lung cancer patients, including 79 with concurrent PE (observation group) and 172 without PE (control group). Demographic, clinical, laboratory, and tumor - related data were collected. Statistical analysis included univariate and multivariate logistic regression to seek independent risk factors and ROC curve analysis to evaluate their potential predictive performance. Univariate analysis revealed significant differences in multiple variables, including pericardial/pleural effusion, smoking index, hematologic parameters, coagulation markers, D - dimer, liver enzymes, albumin, and tumor markers (CEA, CA125, CA199) (P < 0.05). Multivariate logistic regression analysis indicated that smoking index, hemoglobin, PT, direct bilirubin, albumin, and CEA may be independent risk factors for synchronous pulmonary embolism in lung cancer patients. The combination of the six independent risk factors also demonstrated significant predictive potential (AUC = 0.857, sensitivity 79.1%, specificity 79.7%). Lung cancer patients presenting with synchronous PE exhibit a distinct clinical phenotype. The smoking index, hemoglobin, PT, direct bilirubin, albumin, and CEA may be independent predictive factors. D - dimer is a well diagnostic marker. These findings suggest a practical framework to help guide clinical suspicion and encourage targeted diagnostic evaluation for PE at the initial diagnosis of lung cancer, contributing to improved early intervention and patient outcomes.

PMID 43052863
阅读全文 →
PubMedVeterinary medicine and science2026-11-19

Early Changes in Serum Protein Electrophoresis and Gamma Globulin during Initial 4 Weeks of Remdesivir Therapy in FIP Cats.

Khalili Kosar K, Cheraghi Hadi H, Saljooghian Isfahani Mohammad Hossein MH

Feline infectious peritonitis (FIP) is a fatal multisystem inflammatory disorder of cats that was historically considered untreatable before the emergence of direct-acting antivirals. The objective of the study was to evaluate early serial changes in serum protein electrophoresis (SPE) patterns in cats treated with remdesivir for FIP, emphasizing gamma-globulin concentrations and percentages. Animals included eighteen client-owned cats diagnosed with FIP based on clinical presentation, standard clinicopathological profiles, and confirmatory RT-PCR. Cats received remdesivir for 4 weeks and were monitored weekly through clinical examinations and laboratory evaluations. Blood samples were collected at baseline (prior to treatment initiation) and weekly for 4 weeks. The SPE analyzed the blood taken every week for the serum protein fractions, such as albumin and the different globulins, namely α1-, α2-, β1-, β2-, and γ-globulins. The albumin to globulin ratio (A/G ratio) was also determined. Gamma globulins were found to be significantly reduced from a median of 3.1 g/dL at week 2 to a median of 2.2 g/dL at the end of week 4 (p < .05) in cats that showed clinical response. Notably, ROC curve analysis identified that a gamma-globulin percentage <23% at week 4 and 18.96% by week 6 (AUC = 0.9105) was strongly associated with complete clinical recovery and sustained relapse-free remission. Serial monitoring of serum protein electrophoresis, particularly longitudinal trends in gamma-globulin percentages and the A/G ratio, provides an objective, practical biomarker strategy to evaluate treatment response and guide the safe timing of antiviral therapy cessation in cats with FIP.

PMID 43052221
阅读全文 →
PubMedBMC cancer2026-11-19

Treatment outcomes and immuno-nutritional biomarkers in patients with cervical esophageal squamous cell carcinoma treated with induction chemotherapy.

Ono Takeharu T, Nakata Yasunori Y, Chitose Shun-Ich SI, Sueyoshi Shintaro S et al.

Cervical esophageal squamous cell carcinoma arises below the upper esophageal sphincter, often causing dysphagia due to tumor progression. Therefore, some patients with cervical esophageal squamous cell carcinoma become malnourished. Due to its low incidence, limited information is available on prognostic immune-nutritional biomarkers. We retrospectively reviewed 47 patients with resectable cervical esophageal squamous cell carcinoma who underwent induction chemotherapy. Prognostic biomarkers were selected based on their 5-year area under the curve values. The association between the biomarkers and disease-free survival or overall survival was evaluated in univariable and multivariable analyses. The C-reactive protein-albumin-lymphocyte index and high-sensitivity modified Glasgow prognostic score were significantly associated with the induction chemotherapy response. Both the C-reactive protein-albumin-lymphocyte index and the high-sensitivity modified Glasgow prognostic score were significantly associated with disease-free survival and overall survival in univariable analysis. C-reactive protein-albumin-lymphocyte indices were significantly associated with disease-free survival and overall survival in multivariable analysis. The C-reactive protein-albumin-lymphocyte index is a useful prognostic treatment outcome biomarker in patients with cervical esophageal squamous cell carcinoma undergoing induction chemotherapy.

PMID 43052838
阅读全文 →
PubMedNPJ Parkinson's disease2026-11-19

Kidney-inflammation-erythrocyte framework for Parkinson disease risk prediction and progression assessment.

Li Sigen S, Song Qiao Q, Zhou Sihan S, Li Wen W et al.

Parkinson's disease (PD) is increasingly recognized as a systemic disorder involving metabolic and peripheral pathological dysregulation. This study proposed a clinically accessible "Kidney-Inflammation-Erythrocyte" framework to characterize peripheral alterations in PD. We constructed and validated a nomogram for PD screening, identified factors associated with Hoehn and Yahr (H-Y) stages, and explored potential biological associations with disease progression using mediation analysis. 572 participants were included to examine the renal function markers, inflammatory indicators, and erythrocyte parameters. Firstly, after LASSO and multivariable logistic regression analysis, seven predictors, including age, sex, urea nitrogen, albumin, interleukin-6 (IL-6), C-reactive protein, and cystatin C, were used to build the nomogram, which showed good discrimination in the training and validation cohorts. Secondly, IL-6, cystatin C, and red blood cell count also showed stage-dependent changes across H-Y stages. Thirdly, after adjusting for age, sex, BMI, medication history, and comorbidities, mediation analysis showed significant total effects on H-Y stages, but no significant mediation pathways. In summary, this study demonstrates significant associations between the "Kidney-Inflammation-Erythrocyte" framework and PD, supporting the potential value of integrating routine laboratory markers for PD screening and disease monitoring. However, further mechanistic studies are needed to clarify how these peripheral alterations are associated with disease status and progression.

PMID 43052340
阅读全文 →
PubMedEuropean heart journal. Valvular and structural heart disease2026-11-19

Predicting outcomes in tricuspid interventions: risk scores and decision tools.

Maisano Francesco F, Metra Marco M

Transcatheter tricuspid valve interventions (TTVI) have emerged as a therapeutic option for patients with symptomatic tricuspid regurgitation (TR) who remain highly symptomatic despite optimized medical therapy. Clinical outcomes after TTVI depend both on the risk profile of the individual patient and on procedural success. Several clinical, laboratory, and imaging-based scoring systems have been developed over the last decade to aid patient selection, guide timing of referral and counsel patients and their families. This narrative review summarizes contemporary risk models across the diagnostic-therapeutic pathway. For patients managed conservatively, simple clinical tools such as the 4A score and the Tricuspid Regurgitation Impact on Outcomes-right ventricular score have been validated to predict heart-failure hospitalisation and mortality. The model for end-stage liver disease score, originally developed for liver disease, may identify patients with end-organ dysfunction who are unlikely to survive surgery. For those considered for isolated tricuspid valve surgery, the Society of Thoracic Surgeons calculator and the TRI-SCORE provide calibrated estimates of peri-operative mortality, while the recently proposed TRIVALVE and haemoglobin-albumin-lymphocyte-platelet scores focus on patients undergoing transcatheter repair. Finally, anatomical scores such as GLIDE help predict procedural success for transcatheter edge-to-edge repair. Understanding the strengths and limitations of each model is essential to individualize care, facilitate shared decision making and optimize outcomes.

PMID 43053876
阅读全文 →
PubMedMycotoxin research2026-11-19

Biological mycotoxin d​etoxification in dried fruits: food safety challenges and barriers to industrial translation.

Qala Kaoutar K, Abdelmoumen Hanaa H

Despite decades of research demonstrating the detoxification potential of microorganisms and enzymes, biological mycotoxin detoxification has achieved only limited industrial implementation, particularly in dried fruits. This persistent gap between laboratory efficacy and practical application remains one of the major unresolved challenges in the field. Rather than providing another descriptive overview of detoxification mechanisms or biological agents, this critical narrative review examines the scientific, technological, regulatory, and commercial barriers limiting industrial translation. A structured literature search was conducted in Scopus, Web of Science, PubMed/MEDLINE, ScienceDirect, and Google Scholar, supplemented by screening the reference lists of relevant publications. Studies were selected according to their relevance to biological mycotoxin reduction, the mechanisms demonstrated, the food matrices investigated, and their implications for safety and industrial applicability, with priority given to publications from 2020 onward. The review highlights a substantial gap between reported laboratory efficacy and demonstrated applicability to dried fruits, as much of the available evidence derives from culture media, simplified food models, or other matrices, including cereals and feed. The low water activity and high sugar content of dried fruits further complicate the transfer of findings from other food systems. Additional barriers include reversible toxin adsorption, insufficient toxicological characterization of transformation products, methodological heterogeneity, limited process robustness, scale-up challenges, regulatory uncertainty, and economic feasibility. Advancing industrial implementation requires matrix-specific validation in naturally contaminated dried fruits under realistic processing and storage conditions, standardized assessment of detoxification mechanisms, and evidence that toxin reduction translates into a demonstrable decrease in toxicological risk. This review identifies research priorities to support the development of safe, scalable, and economically viable biological interventions for dried-fruit processing.

PMID 43052622
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多albumin